Results 171 to 180 of about 769,731 (345)

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Isolation and eradication of ovarian CD44+ cancer stem cells via Notch signaling pathway mediated by ectopic silence of MAML1

, 2022
Vahideh Keyvani, Seyed Reza Kazemi Nezhad, Meysam Moghbeli, Samaneh Mollazadeh, Mohammad Reza Abbaszadegan   +4 more
openalex   +2 more sources

Engineered Mesenchymal Stem Cell–NK Cell Complexes for Spatially Targeted and Functionally Revitalized Cancer Immunotherapy

Advanced Science, EarlyView.
IL‐15‐engineered stem cell–NK cell complexes, assembled via bioorthogonal chemistry, enable effective lung cancer immunotherapy. Abstract Natural killer (NK) cells represent a powerful immunotherapeutic strategy due to their intrinsic cytotoxicity and ability to target tumor cells independently of antigen presentation.
Qian Zhang, Bo Yin, Munaiwaier Sabier, Youlan Yang, Mengling Wu, Zhouping Zhao, Xuanzhi Luo, Yuehong Zhong, Xiuming Zhu, Jie Zhang, Jing Wang, Kai Chen, Fei Ruan, Wei Zhang, Zhimin Lu, Jiong Wang   +15 more
wiley   +1 more source

Exonuclease 1 (Exo1) Participates in Mammalian Non-Homologous End Joining and Contributes to Drug Resistance in Ovarian Cancer

, 2020
Dongyun He, Tao Li, Minjia Sheng, Ben Yang   +3 more
openalex   +2 more sources

Evaluation of a Hypoxia Regulated Gene Panel in Ovarian Cancer [PDF]

, 2015
Amanda F. Baker, Scott W. Malm, Ritu Pandey, Cindy Laughren, Haiyan Cui, Denise J. Roe, Setsuko K. Chambers   +6 more
openalex   +1 more source

TP019/#1387  Rosella (GOG-3073, ENGOT-OV72/MITO): a phase 3 study of relacorilant + nab paclitaxel vs. nab-paclitaxel in platinum-resistant ovarian cancer [PDF]

, 2023
Domenica Lorusso, Andrea Bagaméri, Erin Bishop, Anita Chudecka-Głaz, Alix Devaux, Laurence Gladieff, Mary E. Gordinier, Jae‐Weon Kim, Jacob Korach, Michael McCollum, Linda Mileshkin, Bradley J. Monk, Shibani Nicum, Angélica Nogueira‐Rodrigues, Ana Oaknin, David M. O’Malley, Mauro Orlando, Lyndah Dreiling, Iulia Cristina Tudor, Alexander Olawaiye   +19 more
openalex   +1 more source

A Biomarker‐Driven Ovary–Endometrium Organ‐on‐a‐Chip Mimicking 3D Multicellular Complexity and Menstrual Cyclicity for Predicting Reproductive Toxicity

Advanced Science, EarlyView.
We present a dual‐organ, biomarker‐integrated ovaryendometrium organ‐on‐a‐chip that recapitulates 3D tissue complexity, menstrual cycle dynamics, and hormonal crosstalk. This platform enables real‐time, cell‐typespecific fluorescent readouts of reproductive toxicity using ANGPTL4 and SERPINB2 as early‐response reporters.
Soo‐Rim Kim, Eun‐kyung Min, Choon‐Mi Lee, Chan Hum Park, Byung‐Chul Oh, YunJae Jung, In‐Sun Hong   +6 more
wiley   +1 more source

miR-214-mediated downregulation of RNF8 induces chromosomal instability in ovarian cancer cells

, 2014
Zheng Wang, Hao Yin, Yuanwei Zhang, Yukun Feng, Zhaofeng Yan, Xiaohua Jiang, Ihtisham Bukhari, Furhan Iqbal, Howard J. Cooke, Qinghua Shi   +9 more
openalex   +1 more source

OPTIMISING THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER: AN ANALYSIS OF PRELIMINARY RESULTS [PDF]

, 2023
О. V. Bondar, А. И. Рыбин, V.E. Maximovskyi, Олена Кузнецова, Sakhadat Alieva   +4 more
openalex   +1 more source

Single‐Cell Computational Frameworks for Quantifying BET Bromodomain Inhibitor Resistance and Screening Re‐Sensitizer Drugs in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
To combat BET inhibitor resistance in triple‐negative breast cancer, we developed two single‐cell computational frameworks. FR20 quantifies resistance by integrating ferroptosis‐related gene signatures, while D‐FR20 screens for potential re‐sensitizers.
Haizhou Liu, Mengqin Yuan, Yini Shang, Jiahao Chen, Fei Hou, Lihong Wang, Wei Jiang   +6 more
wiley   +1 more source